社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
Simm
IP属地：未知
+关注
帖子 · 23
帖子 · 23
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
Simm
Simm
·
2021-08-04
Will the booster jab (3rd jab vaccination) boost the share ptocebof PFE ?
Pfizer hikes 2021 outlook after vaccine boosts sales, profit<blockquote>疫苗提振销售和利润后辉瑞上调2021年展望</blockquote>
Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter
Pfizer hikes 2021 outlook after vaccine boosts sales, profit<blockquote>疫苗提振销售和利润后辉瑞上调2021年展望</blockquote>
看
2,694
回复
1
点赞
4
编组 21备份 2
分享
举报
Simm
Simm
·
2021-08-04
Turn to RED MOON now!
看
903
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
Simm
Simm
·
2021-08-04
Toyota! My trusted car
非常抱歉，此主贴已删除
看
896
回复
1
点赞
4
编组 21备份 2
分享
举报
Simm
Simm
·
2021-08-04
Inari has good prospect! At 18x is a good bargain
3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>
Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021. Key Points Pfi
3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>
看
1,126
回复
2
点赞
9
编组 21备份 2
分享
举报
Simm
Simm
·
2021-07-28
Anyone drinking beers
看
1,234
回复
评论
点赞
1
编组 21备份 2
分享
举报
Simm
Simm
·
2021-07-27
Nice beer, Samual Adam
看
1,366
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
Simm
Simm
·
2021-07-21
😱😱😱
奈雪的茶跌近4% 较招股价已跌超35%
7月21日消息，奈雪的茶持续下跌，现跌3.82%，报13.08港元，最新市值224.34亿港元。 奈雪的茶于6月30日首挂上市，每股定价19.8港元。上市当日破发，此后股价持续下行，今日再度跌近4%，低见12.86港元，较招股价已跌超35%。 海量资讯、精准解读，尽在新浪财经APP
奈雪的茶跌近4% 较招股价已跌超35%
看
1,150
回复
评论
点赞
1
编组 21备份 2
分享
举报
Simm
Simm
·
2021-07-21
What about Nio; Xpeng Lucid etc etc ?
Why Goldman Sachs Is Bullish On Tesla Ahead Of Q2 Earnings<blockquote>为什么高盛在第二季度财报公布前看好特斯拉</blockquote>
Tesla, Inc.(NASDAQ:TSLA)shares have been locked in a lackluster phase in 2021. An upcoming catalyst
Why Goldman Sachs Is Bullish On Tesla Ahead Of Q2 Earnings<blockquote>为什么高盛在第二季度财报公布前看好特斯拉</blockquote>
看
1,378
回复
评论
点赞
6
编组 21备份 2
分享
举报
Simm
Simm
·
2021-07-21
What happen to Blue zmoon? Turning to Red Moon now
非常抱歉，此主贴已删除
看
1,397
回复
1
点赞
7
编组 21备份 2
分享
举报
Simm
Simm
·
2021-07-20
Chewy! Chewy!
看
1,124
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3574328305423311","uuid":"3574328305423311","gmtCreate":1611235097167,"gmtModify":1620450783533,"name":"Simm","pinyin":"simm","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":73,"tweetSize":23,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.02.21","exceedPercentage":"60.23%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":807702702,"gmtCreate":1628054881506,"gmtModify":1633753982176,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574328305423311","idStr":"3574328305423311"},"themes":[],"htmlText":"Will the booster jab (3rd jab vaccination) boost the share ptocebof PFE ?","listText":"Will the booster jab (3rd jab vaccination) boost the share ptocebof PFE ?","text":"Will the booster jab (3rd jab vaccination) boost the share ptocebof PFE ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/807702702","repostId":"1156524625","repostType":4,"repost":{"id":"1156524625","kind":"news","pubTimestamp":1628053893,"share":"https://www.laohu8.com/m/news/1156524625?lang=zh_CN&edition=full","pubTime":"2021-08-04 13:11","market":"us","language":"en","title":"Pfizer hikes 2021 outlook after vaccine boosts sales, profit<blockquote>疫苗提振销售和利润后辉瑞上调2021年展望</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1156524625","media":"Business Hala","summary":"Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter ","content":"<p>Strong sales of its COVID-19 vaccine and other drugs helped<b> <a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> nearly double its second-quarter revenue and boost its profit by 59%, beating Wall Street’s expectations.</p><p><blockquote>其COVID-19疫苗和其他药物的强劲销售有所帮助<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>第二季度营收增长近一倍，利润增长59%，超出华尔街预期。</blockquote></p><p> Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter revenue and boost its profit to 59%, beating Wall Street’s expectations and helping the drug giant look forward to 2021. Helped to rapidly increase sales and profit forecasts.</p><p><blockquote>其COVID-19疫苗和其他药物的强劲销售帮助辉瑞第二季度收入增长了近一倍，利润增长至59%，超出了华尔街的预期，并帮助这家制药巨头展望2021年。帮助快速提高了销售额和利润预测。</blockquote></p><p> Amid the growing coronavirus pandemic, the COVID-19 vaccine became Pfizer’s top seller, generating nearly half of its revenue — $7.84 billion from direct sales and revenue splitting with its partner, Germany’s BioNTech.</p><p><blockquote>在日益严重的冠状病毒大流行中，COVID-19疫苗成为辉瑞最畅销的疫苗，创造了其近一半的收入——78.4亿美元来自直接销售和与其合作伙伴德国BioNTech的收入分成。</blockquote></p><p> Pfizer now forecasts revenue from the two-dose vaccine this year to reach $33.5 billion for the 2.1 billion doses it has been contracted to provide by the end of the year. This does not include the contract signed last week to provide an additional 200 million doses to the US</p><p><blockquote>辉瑞目前预测，今年两剂疫苗的收入将达到335亿美元，其已签约在年底前提供21亿剂疫苗。这还不包括上周签署的向美国额外提供2亿剂疫苗的合同</blockquote></p><p> The New York company revealed on Wednesday that an ongoing trial of a booster shot given six months after the second vaccine dose showed that it increased antibody levels against the more-transmissible delta variant to 11 times higher in older people and younger people. increased more than five times. , compared to levels after two doses. The company also released data showing that six months after vaccination, the shots were 97% effective at preventing serious disease.</p><p><blockquote>这家纽约公司周三透露，正在进行的一项在第二剂疫苗接种六个月后进行的加强注射试验表明，它将老年人和年轻人针对传染性更强的德尔塔变异毒株的抗体水平提高了11倍。增加了五倍多.,与两次给药后的水平相比。该公司还发布的数据显示，接种疫苗六个月后，疫苗在预防严重疾病方面的有效性为97%。</blockquote></p><p> “We are absolutely convinced that a booster will be needed,” CEO Albert Boerla said in an interview, “that a third dose of the original vaccine may be sufficient.” Still, in August Pfizer will begin testing a booster targeting the Delta version in volunteers, because “there’s so much at stake, you can’t take the risk.”</p><p><blockquote>首席执行官Albert Boerla在接受采访时表示：“我们绝对相信需要加强剂，第三剂原始疫苗可能就足够了。”尽管如此，辉瑞将在8月份开始在志愿者中测试针对Delta版本的加强剂，因为“利害攸关，你不能冒这个风险。”</blockquote></p><p> Bourla said Pfizer has delivered more than 1 billion doses of the vaccine globally and expects to make 3 billion doses this year, with many more going to low- and middle-income countries. So far, most of the doses of all COVID-19 vaccines produced in Europe and the US have gone to rich countries.</p><p><blockquote>Bourla表示，辉瑞已在全球交付了超过10亿剂疫苗，预计今年将生产30亿剂，其中更多将销往中低收入国家。到目前为止，欧洲和美国生产的所有新冠肺炎疫苗的大部分剂量都流向了富裕国家。</blockquote></p><p> By the end of September, trials in 5- to 11-year-old volunteers should produce the safety and efficacy data necessary to obtain emergency use authorization in that age group, and data on trials in children 6 months to 5 years of age should be used. must comply. Soon according to Pfizer.</p><p><blockquote>到9月底，在5至11岁志愿者中进行的试验应产生在该年龄组中获得紧急使用授权所需的安全性和有效性数据，并应使用在6个月至5岁儿童中进行的试验数据。必须遵守。据辉瑞称，很快。</blockquote></p><p> The US Food and Drug Administration is now reviewing data that could lead to full approval of the vaccine for adults, which Borla said could reduce hesitation from vaccination.</p><p><blockquote>美国食品和药物管理局目前正在审查可能导致成人疫苗完全批准的数据，Borla表示，这可能会减少接种疫苗的犹豫。</blockquote></p><p> Second-quarter net income was $5.56 billion, or 98 cents per share, up from $3.49 billion, or 62 cents per share.</p><p><blockquote>第二季度净利润为55.6亿美元，合每股98美分，高于34.9亿美元，合每股62美分。</blockquote></p><p> Adjusted earnings, excluding one-time gains and losses, amounted to $6.08 billion, or $1.07 per share, significantly higher than Wall Street’s 97 cents.</p><p><blockquote>不包括一次性损益的调整后收益为60.8亿美元，即每股1.07美元，明显高于华尔街的97美分。</blockquote></p><p> Its quarterly revenue of $18.98 billion is up from last year’s $9.86 billion, and also topped estimates.</p><p><blockquote>其季度收入为189.8亿美元，高于去年的98.6亿美元，也超出了预期。</blockquote></p><p> Pfizer shares rose $1.46, or 3.5%, to $43.56, near a 52-week high.</p><p><blockquote>辉瑞股价上涨1.46美元，涨幅3.5%，至43.56美元，接近52周高点。</blockquote></p><p> Sales of Pfizer’s drugs for cancer and rare diseases, as well as drugs primarily used in hospitals, grew double-digit. Sales of Eliquis for preventing blood clots and stroke rose 16% to $1.48 billion, while Ibrance’s sales rose 4% to $1.4 billion in the quarter.</p><p><blockquote>辉瑞治疗癌症和罕见病的药物以及主要用于医院的药物的销售额增长了两位数。本季度用于预防血栓和中风的Eliquis销售额增长16%至14.8亿美元，而Ibrance销售额增长4%至14亿美元。</blockquote></p><p> Pfizer’s pneumonia vaccine Prevnar 13 – the world’s most lucrative vaccine by far – climbed 11% in sales to $1.24 billion amid the pandemic. The company won US approval in June for Prevnar 20, an updated version for adults that protects against seven more strains of pneumococcal disease.</p><p><blockquote>辉瑞的肺炎疫苗Prevnar 13——迄今为止世界上最赚钱的疫苗——在疫情期间销售额增长了11%，达到12.4亿美元。该公司于6月获得了Prevnar 20的美国批准，这是一种针对成人的更新版本，可预防另外七种肺炎球菌疾病。</blockquote></p><p> In May, Pfizer and partner Myovent received approval for MyFembry to reduce heavy menstrual bleeding due to uterine fibroids in premenopausal women.</p><p><blockquote>5月，辉瑞和合作伙伴Myovent获得MyFembry的批准，用于减少绝经前妇女因子宫肌瘤导致的大量月经出血。</blockquote></p><p> Pfizer’s head of research Mikel Dolstein outlined eight major research programs with the potential to have a major impact on public health, including a pill to treat COVID-19 and vaccines against Lyme disease and respiratory syncytial virus, which occur each year. Infects and kills more than 5% of adults. about 15,000 of them in the US</p><p><blockquote>辉瑞的研究主管Mikel Dolstein概述了八个有可能对公共卫生产生重大影响的主要研究项目，包括治疗COVID-19的药丸以及每年都会发生的莱姆病和呼吸道合胞病毒的疫苗。感染并杀死超过5%的成年人。其中大约15,000人在美国</blockquote></p><p> Pfizer now expects adjusted full-year earnings in the range of $3.95 to $4.05 per share, up from its May forecast of $3.55 to $3.65 per share, and revenue in the range of $78 billion to $80 billion. , from $70.5 billion to $72.5 billion.</p><p><blockquote>辉瑞目前预计调整后的全年收益将在每股3.95美元至4.05美元之间，高于5月份预期的每股3.55美元至3.65美元，营收将在780亿美元至800亿美元之间，从705亿美元增至725亿美元。</blockquote></p><p></p>","source":"lsy1627951004805","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer hikes 2021 outlook after vaccine boosts sales, profit<blockquote>疫苗提振销售和利润后辉瑞上调2021年展望</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer hikes 2021 outlook after vaccine boosts sales, profit<blockquote>疫苗提振销售和利润后辉瑞上调2021年展望</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Business Hala</strong><span class=\"h-time small\">2021-08-04 13:11</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Strong sales of its COVID-19 vaccine and other drugs helped<b> <a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> nearly double its second-quarter revenue and boost its profit by 59%, beating Wall Street’s expectations.</p><p><blockquote>其COVID-19疫苗和其他药物的强劲销售有所帮助<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>第二季度营收增长近一倍，利润增长59%，超出华尔街预期。</blockquote></p><p> Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter revenue and boost its profit to 59%, beating Wall Street’s expectations and helping the drug giant look forward to 2021. Helped to rapidly increase sales and profit forecasts.</p><p><blockquote>其COVID-19疫苗和其他药物的强劲销售帮助辉瑞第二季度收入增长了近一倍，利润增长至59%，超出了华尔街的预期，并帮助这家制药巨头展望2021年。帮助快速提高了销售额和利润预测。</blockquote></p><p> Amid the growing coronavirus pandemic, the COVID-19 vaccine became Pfizer’s top seller, generating nearly half of its revenue — $7.84 billion from direct sales and revenue splitting with its partner, Germany’s BioNTech.</p><p><blockquote>在日益严重的冠状病毒大流行中，COVID-19疫苗成为辉瑞最畅销的疫苗，创造了其近一半的收入——78.4亿美元来自直接销售和与其合作伙伴德国BioNTech的收入分成。</blockquote></p><p> Pfizer now forecasts revenue from the two-dose vaccine this year to reach $33.5 billion for the 2.1 billion doses it has been contracted to provide by the end of the year. This does not include the contract signed last week to provide an additional 200 million doses to the US</p><p><blockquote>辉瑞目前预测，今年两剂疫苗的收入将达到335亿美元，其已签约在年底前提供21亿剂疫苗。这还不包括上周签署的向美国额外提供2亿剂疫苗的合同</blockquote></p><p> The New York company revealed on Wednesday that an ongoing trial of a booster shot given six months after the second vaccine dose showed that it increased antibody levels against the more-transmissible delta variant to 11 times higher in older people and younger people. increased more than five times. , compared to levels after two doses. The company also released data showing that six months after vaccination, the shots were 97% effective at preventing serious disease.</p><p><blockquote>这家纽约公司周三透露，正在进行的一项在第二剂疫苗接种六个月后进行的加强注射试验表明，它将老年人和年轻人针对传染性更强的德尔塔变异毒株的抗体水平提高了11倍。增加了五倍多.,与两次给药后的水平相比。该公司还发布的数据显示，接种疫苗六个月后，疫苗在预防严重疾病方面的有效性为97%。</blockquote></p><p> “We are absolutely convinced that a booster will be needed,” CEO Albert Boerla said in an interview, “that a third dose of the original vaccine may be sufficient.” Still, in August Pfizer will begin testing a booster targeting the Delta version in volunteers, because “there’s so much at stake, you can’t take the risk.”</p><p><blockquote>首席执行官Albert Boerla在接受采访时表示：“我们绝对相信需要加强剂，第三剂原始疫苗可能就足够了。”尽管如此，辉瑞将在8月份开始在志愿者中测试针对Delta版本的加强剂，因为“利害攸关，你不能冒这个风险。”</blockquote></p><p> Bourla said Pfizer has delivered more than 1 billion doses of the vaccine globally and expects to make 3 billion doses this year, with many more going to low- and middle-income countries. So far, most of the doses of all COVID-19 vaccines produced in Europe and the US have gone to rich countries.</p><p><blockquote>Bourla表示，辉瑞已在全球交付了超过10亿剂疫苗，预计今年将生产30亿剂，其中更多将销往中低收入国家。到目前为止，欧洲和美国生产的所有新冠肺炎疫苗的大部分剂量都流向了富裕国家。</blockquote></p><p> By the end of September, trials in 5- to 11-year-old volunteers should produce the safety and efficacy data necessary to obtain emergency use authorization in that age group, and data on trials in children 6 months to 5 years of age should be used. must comply. Soon according to Pfizer.</p><p><blockquote>到9月底，在5至11岁志愿者中进行的试验应产生在该年龄组中获得紧急使用授权所需的安全性和有效性数据，并应使用在6个月至5岁儿童中进行的试验数据。必须遵守。据辉瑞称，很快。</blockquote></p><p> The US Food and Drug Administration is now reviewing data that could lead to full approval of the vaccine for adults, which Borla said could reduce hesitation from vaccination.</p><p><blockquote>美国食品和药物管理局目前正在审查可能导致成人疫苗完全批准的数据，Borla表示，这可能会减少接种疫苗的犹豫。</blockquote></p><p> Second-quarter net income was $5.56 billion, or 98 cents per share, up from $3.49 billion, or 62 cents per share.</p><p><blockquote>第二季度净利润为55.6亿美元，合每股98美分，高于34.9亿美元，合每股62美分。</blockquote></p><p> Adjusted earnings, excluding one-time gains and losses, amounted to $6.08 billion, or $1.07 per share, significantly higher than Wall Street’s 97 cents.</p><p><blockquote>不包括一次性损益的调整后收益为60.8亿美元，即每股1.07美元，明显高于华尔街的97美分。</blockquote></p><p> Its quarterly revenue of $18.98 billion is up from last year’s $9.86 billion, and also topped estimates.</p><p><blockquote>其季度收入为189.8亿美元，高于去年的98.6亿美元，也超出了预期。</blockquote></p><p> Pfizer shares rose $1.46, or 3.5%, to $43.56, near a 52-week high.</p><p><blockquote>辉瑞股价上涨1.46美元，涨幅3.5%，至43.56美元，接近52周高点。</blockquote></p><p> Sales of Pfizer’s drugs for cancer and rare diseases, as well as drugs primarily used in hospitals, grew double-digit. Sales of Eliquis for preventing blood clots and stroke rose 16% to $1.48 billion, while Ibrance’s sales rose 4% to $1.4 billion in the quarter.</p><p><blockquote>辉瑞治疗癌症和罕见病的药物以及主要用于医院的药物的销售额增长了两位数。本季度用于预防血栓和中风的Eliquis销售额增长16%至14.8亿美元，而Ibrance销售额增长4%至14亿美元。</blockquote></p><p> Pfizer’s pneumonia vaccine Prevnar 13 – the world’s most lucrative vaccine by far – climbed 11% in sales to $1.24 billion amid the pandemic. The company won US approval in June for Prevnar 20, an updated version for adults that protects against seven more strains of pneumococcal disease.</p><p><blockquote>辉瑞的肺炎疫苗Prevnar 13——迄今为止世界上最赚钱的疫苗——在疫情期间销售额增长了11%，达到12.4亿美元。该公司于6月获得了Prevnar 20的美国批准，这是一种针对成人的更新版本，可预防另外七种肺炎球菌疾病。</blockquote></p><p> In May, Pfizer and partner Myovent received approval for MyFembry to reduce heavy menstrual bleeding due to uterine fibroids in premenopausal women.</p><p><blockquote>5月，辉瑞和合作伙伴Myovent获得MyFembry的批准，用于减少绝经前妇女因子宫肌瘤导致的大量月经出血。</blockquote></p><p> Pfizer’s head of research Mikel Dolstein outlined eight major research programs with the potential to have a major impact on public health, including a pill to treat COVID-19 and vaccines against Lyme disease and respiratory syncytial virus, which occur each year. Infects and kills more than 5% of adults. about 15,000 of them in the US</p><p><blockquote>辉瑞的研究主管Mikel Dolstein概述了八个有可能对公共卫生产生重大影响的主要研究项目，包括治疗COVID-19的药丸以及每年都会发生的莱姆病和呼吸道合胞病毒的疫苗。感染并杀死超过5%的成年人。其中大约15,000人在美国</blockquote></p><p> Pfizer now expects adjusted full-year earnings in the range of $3.95 to $4.05 per share, up from its May forecast of $3.55 to $3.65 per share, and revenue in the range of $78 billion to $80 billion. , from $70.5 billion to $72.5 billion.</p><p><blockquote>辉瑞目前预计调整后的全年收益将在每股3.95美元至4.05美元之间，高于5月份预期的每股3.55美元至3.65美元，营收将在780亿美元至800亿美元之间，从705亿美元增至725亿美元。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://businesshala.com/pfizer-hikes-2021-outlook-after-vaccine-boosts-sales-profit/\">Business Hala</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://businesshala.com/pfizer-hikes-2021-outlook-after-vaccine-boosts-sales-profit/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156524625","content_text":"Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter revenue and boost its profit by 59%, beating Wall Street’s expectations.\n\nStrong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter revenue and boost its profit to 59%, beating Wall Street’s expectations and helping the drug giant look forward to 2021. Helped to rapidly increase sales and profit forecasts.\nAmid the growing coronavirus pandemic, the COVID-19 vaccine became Pfizer’s top seller, generating nearly half of its revenue — $7.84 billion from direct sales and revenue splitting with its partner, Germany’s BioNTech.\nPfizer now forecasts revenue from the two-dose vaccine this year to reach $33.5 billion for the 2.1 billion doses it has been contracted to provide by the end of the year. This does not include the contract signed last week to provide an additional 200 million doses to the US\nThe New York company revealed on Wednesday that an ongoing trial of a booster shot given six months after the second vaccine dose showed that it increased antibody levels against the more-transmissible delta variant to 11 times higher in older people and younger people. increased more than five times. , compared to levels after two doses. The company also released data showing that six months after vaccination, the shots were 97% effective at preventing serious disease.\n“We are absolutely convinced that a booster will be needed,” CEO Albert Boerla said in an interview, “that a third dose of the original vaccine may be sufficient.” Still, in August Pfizer will begin testing a booster targeting the Delta version in volunteers, because “there’s so much at stake, you can’t take the risk.”\nBourla said Pfizer has delivered more than 1 billion doses of the vaccine globally and expects to make 3 billion doses this year, with many more going to low- and middle-income countries. So far, most of the doses of all COVID-19 vaccines produced in Europe and the US have gone to rich countries.\nBy the end of September, trials in 5- to 11-year-old volunteers should produce the safety and efficacy data necessary to obtain emergency use authorization in that age group, and data on trials in children 6 months to 5 years of age should be used. must comply. Soon according to Pfizer.\nThe US Food and Drug Administration is now reviewing data that could lead to full approval of the vaccine for adults, which Borla said could reduce hesitation from vaccination.\nSecond-quarter net income was $5.56 billion, or 98 cents per share, up from $3.49 billion, or 62 cents per share.\nAdjusted earnings, excluding one-time gains and losses, amounted to $6.08 billion, or $1.07 per share, significantly higher than Wall Street’s 97 cents.\nIts quarterly revenue of $18.98 billion is up from last year’s $9.86 billion, and also topped estimates.\nPfizer shares rose $1.46, or 3.5%, to $43.56, near a 52-week high.\nSales of Pfizer’s drugs for cancer and rare diseases, as well as drugs primarily used in hospitals, grew double-digit. Sales of Eliquis for preventing blood clots and stroke rose 16% to $1.48 billion, while Ibrance’s sales rose 4% to $1.4 billion in the quarter.\nPfizer’s pneumonia vaccine Prevnar 13 – the world’s most lucrative vaccine by far – climbed 11% in sales to $1.24 billion amid the pandemic. The company won US approval in June for Prevnar 20, an updated version for adults that protects against seven more strains of pneumococcal disease.\nIn May, Pfizer and partner Myovent received approval for MyFembry to reduce heavy menstrual bleeding due to uterine fibroids in premenopausal women.\nPfizer’s head of research Mikel Dolstein outlined eight major research programs with the potential to have a major impact on public health, including a pill to treat COVID-19 and vaccines against Lyme disease and respiratory syncytial virus, which occur each year. Infects and kills more than 5% of adults. about 15,000 of them in the US\nPfizer now expects adjusted full-year earnings in the range of $3.95 to $4.05 per share, up from its May forecast of $3.55 to $3.65 per share, and revenue in the range of $78 billion to $80 billion. , from $70.5 billion to $72.5 billion.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2694,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807706941,"gmtCreate":1628054725583,"gmtModify":1633753983574,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574328305423311","idStr":"3574328305423311"},"themes":[],"htmlText":"Turn to RED MOON now!","listText":"Turn to RED MOON now!","text":"Turn to RED MOON now!","images":[{"img":"https://static.tigerbbs.com/2ef0259d7e3fb071dde7bf5e6836d5ba","width":"1125","height":"2083"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/807706941","isVote":1,"tweetType":1,"viewCount":903,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":807700409,"gmtCreate":1628054431501,"gmtModify":1633753985921,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574328305423311","idStr":"3574328305423311"},"themes":[],"htmlText":"Toyota! My trusted car","listText":"Toyota! My trusted car","text":"Toyota! My trusted car","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/807700409","repostId":"1136976094","repostType":4,"isVote":1,"tweetType":1,"viewCount":896,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807477898,"gmtCreate":1628054319814,"gmtModify":1633753987039,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574328305423311","idStr":"3574328305423311"},"themes":[],"htmlText":"Inari has good prospect! At 18x is a good bargain","listText":"Inari has good prospect! At 18x is a good bargain","text":"Inari has good prospect! At 18x is a good bargain","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/807477898","repostId":"1124757232","repostType":4,"repost":{"id":"1124757232","kind":"news","pubTimestamp":1628045612,"share":"https://www.laohu8.com/m/news/1124757232?lang=zh_CN&edition=full","pubTime":"2021-08-04 10:53","market":"us","language":"en","title":"3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1124757232","media":"The Motley Fool","summary":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfi","content":"<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p><p><blockquote><b><i>这就是为什么辉瑞、Inari Medical和Novavax的股票在2021年可能更有价值。</i></b></blockquote></p><p> <b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul> <li>Pfizer might surprise to the upside.</li> <li>Inari Medical is growing like gangbusters.</li> <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li> </ul> COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p><p><blockquote><ul><li>辉瑞可能会带来惊喜。</li><li>伊那里医疗公司正在飞速发展。</li><li>随着COVID-19病毒的变异，Novavax的疫苗可能是一剂重要的加强针。</li></ul>2020年，新冠肺炎和国际封锁导致世界经济崩溃。许多人已经接种了疫苗，并期待正常化。但COVID正在变异，新的德尔塔变异毒株可能会给世界的重新开放带来麻烦。投资者如何保护自己？</blockquote></p><p> A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p><p><blockquote>Motley Fool撰稿人小组为医疗保健股提供了三个想法，即使新冠疫情形势恶化，这些股票也将在2021年飙升。阅读更多内容，了解为什么您可能想购买<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">伊那里医疗公司。</a></b>，和<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <h3><b>Pfizer: More room to run</b></h3> <b>George Budwell</b> <b>(Pfizer):</b> American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> -- losing steam from a sales perspective starting in 2022.</p><p><blockquote><h3><b>辉瑞：更多运行空间</b></h3><b>乔治·布德维尔</b> <b>（辉瑞）：</b>在目前的新冠疫苗公司中，美国制药巨头辉瑞听起来可能不是一个性感的选择。华尔街目前的共识是制药商Comirnaty的疫苗——与<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>——从2022年开始，从销售角度来看失去动力。</blockquote></p><p> Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p><p><blockquote>然而，由于德尔塔变异毒株，Comirnaty的商业寿命可能会比最初预期的长得多。虽然高传播变种的出现对整个社会来说显然是个坏消息，但辉瑞及其股东可能会从这一不幸的发展中受益。</blockquote></p><p> There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p><p><blockquote>有两个明显的理由认为辉瑞的股价可能会因达美航空问题而走高。首先，该公司宣布，最早可能在本月提交第三次加强注射的紧急使用授权。其次，辉瑞计划本月启动德尔塔特异性版本疫苗的临床试验。</blockquote></p><p> Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p><p><blockquote>尽管美国食品药品监督管理局和疾病控制与预防中心最近都淡化了加强注射的必要性，但辉瑞已经提出了第三次注射的令人信服的理由，以应对德尔塔变异毒株的猖獗传播和Comirnaty在完全接种疫苗后6至12个月的疗效减弱。</blockquote></p><p> The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p><p><blockquote>对于投资者来说，总体情况是，辉瑞2022年的收入可能比2021年增长9.7%——也就是说，如果加强注射确实获得批准，并且该公司还成功开发了delta特异性疫苗。相比之下，华尔街目前预计该制药商明年的营收将比2021年下降14.8%。</blockquote></p><p> Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.</p><p><blockquote>辉瑞的股票可能走向何方？从保守的角度来看，如果疫苗方面的所有部分都到位，股价应该会达到50美元。这比该制药商的股价目前上涨了大约17%，甚至还没有考虑到该公司当前水平上颇具吸引力的3.64%股息收益率。简而言之，如果这种情况实现，辉瑞的股票交易价格将仅为2022年销售额的约3.5倍，对于派息的大型制药股来说，这是一个相当适中的估值。</blockquote></p><p> <h3><b>Inari Medical: Skyrocketing Sales</b></h3> <b>Patrick Bafuma</b> <b>(Inari Medical):</b> If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to <i>The New York Times</i> -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p><p><blockquote><h3><b>伊那里医疗：销售额暴涨</b></h3><b>帕特里克·巴富马</b> <b>（伊那里医疗）：</b>如果您正在寻找一只在大流行的顺风消退后具有持久力的股票，请关注伊那里医疗。数据显示，2021年7月27日新增108,000例新冠病例，为2021年2月5日以来最多<i>纽约时报</i>——这个数字是7月初7天平均水平的八倍多。更糟糕的是，COVID不仅会导致呼吸困难，还会使患者患致残和可能危及生命的血栓的风险增加两倍以上。我们仍然不确定当患者无症状或轻度COVID感染时，接种疫苗是否能完全降低血栓的风险。</blockquote></p><p></p><p> This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p><p><blockquote>对于一家商业阶段的医疗技术公司来说，这似乎是一个很好的设置，该公司开发了微创产品，旨在消除大血凝块，而不需要强大的血栓破坏药物。通过使用ClotTriever和FlowTriever设备，伊那里迄今已治疗了25,000多名患者。2021年第一季度，临床医生使用该公司的设备进行了约5,500次手术，比去年同季度增长130%，比2020年第四季度增长约20%。根据数据，截至7月27日，美国约有12%的新冠肺炎患者出现血栓，约有35,000人因新冠肺炎住院（并且还在增加）<i>纽约时报</i>，伊那里可能会看到符合条件的病例增加。</blockquote></p><p> Not to mention the company's results thus far for blood clots in the lung are spectacular:</p><p><blockquote>更不用说该公司迄今为止在肺部血栓方面的结果非常惊人：</blockquote></p><p> <ul> <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li> <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li> <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li> <li>No ICU stays are required after the procedure.</li> </ul> Add it all up, and Inari's retrieval device seems like an obvious choice.</p><p><blockquote><ul><li>由于肺部中高风险血栓的历史30天死亡率为9.7%，伊那里0.4%的30天死亡率令人印象深刻。</li><li>30天再入院率降低了6.7%，而常规护理为24.4%。</li><li>48小时内的主要不良事件发生率仅为1.3%。</li><li>手术后不需要住ICU。</li></ul>所有这些加起来，伊那里的检索设备似乎是一个显而易见的选择。</blockquote></p><p> The company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p><p><blockquote>该公司第一季度收入同比增长113%，环比增长18%，2021年第一季度毛利率为91.9%。因此，伊那里的市销率为18，使其成为一只正在出售的成长型股票。</blockquote></p><p> Inari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p><p><blockquote>Inari在价值38亿美元的美国市场的渗透率不到5%，今年早些时候在欧洲推出的市场也有很大的增长空间。这意味着这家市值45亿美元的公司有很多机会。虽然COVID影响了许多选择性和半选择性程序，但它显然没有减缓伊那里，甚至可能加速其吸收。</blockquote></p><p> <h3><b>Novavax: How high can it go?</b></h3> <b>Taylor Carmichael</b> <b>(Novavax):</b> The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p><p><blockquote><h3><b>Novavax：能涨到多高？</b></h3><b>泰勒·卡迈克尔</b> <b>（诺瓦瓦克斯）：</b>疫苗生物技术公司Novavax在2020年表现出色，由于对其COVID疫苗的乐观情绪，其股价上涨了2700%。虽然该公司尚未申请紧急使用授权，但预计将在本季度申请。2021年迄今为止，该股已上涨60%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的NVAX数据。</span></p></blockquote></p><p> Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p><p><blockquote>COVID-19疫苗第三阶段的积极数据导致该股在今年年初飙升，但由于该公司的疫苗上市延迟，股价已经回落。首先，制造疫苗所需的原材料短缺。现在，该公司必须证明其各种合同生产设施将保持所有地点的疫苗质量一致。</blockquote></p><p> Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p><p><blockquote>尽管存在这些延迟，但长期投资者有理由看涨。制造业正在扩大规模，预计到第三季度末，生产率将达到每月1亿剂，到12月将达到每月1.5亿剂。虽然美国的许多人已经接种了疫苗，但世界其他地方的机会相当大。Novavax已向COVAX（国际疫苗联盟）预售了11亿剂疫苗，并已签约在全球范围内供应数亿剂疫苗。</blockquote></p><p> In the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told <i>The New York Times</i>.</p><p><blockquote>在美国，Novavax疫苗可能主要用于已经接种疫苗的人的加强注射。FDA代理首席科学家露丝安娜·博里奥(Luciana Borio)博士表示：“它们可能确实适合加强剂。”从2015年到2017年，告诉<i>纽约时报</i>.</blockquote></p><p> Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p><p><blockquote>未来，Novavax计划将其新冠疫苗与流感疫苗结合起来，形成一种一次性疗法。虽然COVID的变异速度不如流感，但我们在过去一年中已经看到了几种变异毒株。在未来的几年里，我们很可能需要不止一次接种疫苗。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Motley Fool</strong><span class=\"h-time small\">2021-08-04 10:53</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p><p><blockquote><b><i>这就是为什么辉瑞、Inari Medical和Novavax的股票在2021年可能更有价值。</i></b></blockquote></p><p> <b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul> <li>Pfizer might surprise to the upside.</li> <li>Inari Medical is growing like gangbusters.</li> <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li> </ul> COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p><p><blockquote><ul><li>辉瑞可能会带来惊喜。</li><li>伊那里医疗公司正在飞速发展。</li><li>随着COVID-19病毒的变异，Novavax的疫苗可能是一剂重要的加强针。</li></ul>2020年，新冠肺炎和国际封锁导致世界经济崩溃。许多人已经接种了疫苗，并期待正常化。但COVID正在变异，新的德尔塔变异毒株可能会给世界的重新开放带来麻烦。投资者如何保护自己？</blockquote></p><p> A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p><p><blockquote>Motley Fool撰稿人小组为医疗保健股提供了三个想法，即使新冠疫情形势恶化，这些股票也将在2021年飙升。阅读更多内容，了解为什么您可能想购买<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">伊那里医疗公司。</a></b>，和<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <h3><b>Pfizer: More room to run</b></h3> <b>George Budwell</b> <b>(Pfizer):</b> American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> -- losing steam from a sales perspective starting in 2022.</p><p><blockquote><h3><b>辉瑞：更多运行空间</b></h3><b>乔治·布德维尔</b> <b>（辉瑞）：</b>在目前的新冠疫苗公司中，美国制药巨头辉瑞听起来可能不是一个性感的选择。华尔街目前的共识是制药商Comirnaty的疫苗——与<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>——从2022年开始，从销售角度来看失去动力。</blockquote></p><p> Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p><p><blockquote>然而，由于德尔塔变异毒株，Comirnaty的商业寿命可能会比最初预期的长得多。虽然高传播变种的出现对整个社会来说显然是个坏消息，但辉瑞及其股东可能会从这一不幸的发展中受益。</blockquote></p><p> There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p><p><blockquote>有两个明显的理由认为辉瑞的股价可能会因达美航空问题而走高。首先，该公司宣布，最早可能在本月提交第三次加强注射的紧急使用授权。其次，辉瑞计划本月启动德尔塔特异性版本疫苗的临床试验。</blockquote></p><p> Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p><p><blockquote>尽管美国食品药品监督管理局和疾病控制与预防中心最近都淡化了加强注射的必要性，但辉瑞已经提出了第三次注射的令人信服的理由，以应对德尔塔变异毒株的猖獗传播和Comirnaty在完全接种疫苗后6至12个月的疗效减弱。</blockquote></p><p> The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p><p><blockquote>对于投资者来说，总体情况是，辉瑞2022年的收入可能比2021年增长9.7%——也就是说，如果加强注射确实获得批准，并且该公司还成功开发了delta特异性疫苗。相比之下，华尔街目前预计该制药商明年的营收将比2021年下降14.8%。</blockquote></p><p> Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.</p><p><blockquote>辉瑞的股票可能走向何方？从保守的角度来看，如果疫苗方面的所有部分都到位，股价应该会达到50美元。这比该制药商的股价目前上涨了大约17%，甚至还没有考虑到该公司当前水平上颇具吸引力的3.64%股息收益率。简而言之，如果这种情况实现，辉瑞的股票交易价格将仅为2022年销售额的约3.5倍，对于派息的大型制药股来说，这是一个相当适中的估值。</blockquote></p><p> <h3><b>Inari Medical: Skyrocketing Sales</b></h3> <b>Patrick Bafuma</b> <b>(Inari Medical):</b> If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to <i>The New York Times</i> -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p><p><blockquote><h3><b>伊那里医疗：销售额暴涨</b></h3><b>帕特里克·巴富马</b> <b>（伊那里医疗）：</b>如果您正在寻找一只在大流行的顺风消退后具有持久力的股票，请关注伊那里医疗。数据显示，2021年7月27日新增108,000例新冠病例，为2021年2月5日以来最多<i>纽约时报</i>——这个数字是7月初7天平均水平的八倍多。更糟糕的是，COVID不仅会导致呼吸困难，还会使患者患致残和可能危及生命的血栓的风险增加两倍以上。我们仍然不确定当患者无症状或轻度COVID感染时，接种疫苗是否能完全降低血栓的风险。</blockquote></p><p></p><p> This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p><p><blockquote>对于一家商业阶段的医疗技术公司来说，这似乎是一个很好的设置，该公司开发了微创产品，旨在消除大血凝块，而不需要强大的血栓破坏药物。通过使用ClotTriever和FlowTriever设备，伊那里迄今已治疗了25,000多名患者。2021年第一季度，临床医生使用该公司的设备进行了约5,500次手术，比去年同季度增长130%，比2020年第四季度增长约20%。根据数据，截至7月27日，美国约有12%的新冠肺炎患者出现血栓，约有35,000人因新冠肺炎住院（并且还在增加）<i>纽约时报</i>，伊那里可能会看到符合条件的病例增加。</blockquote></p><p> Not to mention the company's results thus far for blood clots in the lung are spectacular:</p><p><blockquote>更不用说该公司迄今为止在肺部血栓方面的结果非常惊人：</blockquote></p><p> <ul> <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li> <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li> <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li> <li>No ICU stays are required after the procedure.</li> </ul> Add it all up, and Inari's retrieval device seems like an obvious choice.</p><p><blockquote><ul><li>由于肺部中高风险血栓的历史30天死亡率为9.7%，伊那里0.4%的30天死亡率令人印象深刻。</li><li>30天再入院率降低了6.7%，而常规护理为24.4%。</li><li>48小时内的主要不良事件发生率仅为1.3%。</li><li>手术后不需要住ICU。</li></ul>所有这些加起来，伊那里的检索设备似乎是一个显而易见的选择。</blockquote></p><p> The company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p><p><blockquote>该公司第一季度收入同比增长113%，环比增长18%，2021年第一季度毛利率为91.9%。因此，伊那里的市销率为18，使其成为一只正在出售的成长型股票。</blockquote></p><p> Inari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p><p><blockquote>Inari在价值38亿美元的美国市场的渗透率不到5%，今年早些时候在欧洲推出的市场也有很大的增长空间。这意味着这家市值45亿美元的公司有很多机会。虽然COVID影响了许多选择性和半选择性程序，但它显然没有减缓伊那里，甚至可能加速其吸收。</blockquote></p><p> <h3><b>Novavax: How high can it go?</b></h3> <b>Taylor Carmichael</b> <b>(Novavax):</b> The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p><p><blockquote><h3><b>Novavax：能涨到多高？</b></h3><b>泰勒·卡迈克尔</b> <b>（诺瓦瓦克斯）：</b>疫苗生物技术公司Novavax在2020年表现出色，由于对其COVID疫苗的乐观情绪，其股价上涨了2700%。虽然该公司尚未申请紧急使用授权，但预计将在本季度申请。2021年迄今为止，该股已上涨60%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的NVAX数据。</span></p></blockquote></p><p> Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p><p><blockquote>COVID-19疫苗第三阶段的积极数据导致该股在今年年初飙升，但由于该公司的疫苗上市延迟，股价已经回落。首先，制造疫苗所需的原材料短缺。现在，该公司必须证明其各种合同生产设施将保持所有地点的疫苗质量一致。</blockquote></p><p> Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p><p><blockquote>尽管存在这些延迟，但长期投资者有理由看涨。制造业正在扩大规模，预计到第三季度末，生产率将达到每月1亿剂，到12月将达到每月1.5亿剂。虽然美国的许多人已经接种了疫苗，但世界其他地方的机会相当大。Novavax已向COVAX（国际疫苗联盟）预售了11亿剂疫苗，并已签约在全球范围内供应数亿剂疫苗。</blockquote></p><p> In the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told <i>The New York Times</i>.</p><p><blockquote>在美国，Novavax疫苗可能主要用于已经接种疫苗的人的加强注射。FDA代理首席科学家露丝安娜·博里奥(Luciana Borio)博士表示：“它们可能确实适合加强剂。”从2015年到2017年，告诉<i>纽约时报</i>.</blockquote></p><p> Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p><p><blockquote>未来，Novavax计划将其新冠疫苗与流感疫苗结合起来，形成一种一次性疗法。虽然COVID的变异速度不如流感，但我们在过去一年中已经看到了几种变异毒株。在未来的几年里，我们很可能需要不止一次接种疫苗。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/\">The Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞","NARI":"Inari Medical, Inc."},"source_url":"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124757232","content_text":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfizer might surprise to the upside.\nInari Medical is growing like gangbusters.\nNovavax's vaccine might be an important booster shot as the COVID-19 virus mutates.\n\nCOVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?\nA panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of Pfizer, Inari Medical, Inc., and Novavax.\nIMAGE SOURCE: GETTY IMAGES.\nPfizer: More room to run\nGeorge Budwell (Pfizer): American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with BioNTech SE -- losing steam from a sales perspective starting in 2022.\nBecause of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.\nThere are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.\nAlthough the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.\nThe big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.\nWhere is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.\nInari Medical: Skyrocketing Sales\nPatrick Bafuma (Inari Medical): If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to The New York Times -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.\nThis seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according toThe Times, Inari is likely to see an uptick in eligible cases.\nNot to mention the company's results thus far for blood clots in the lung are spectacular:\n\nWith the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.\nThere's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.\nMajor adverse events within 48 hours occur at only a 1.3% rate.\nNo ICU stays are required after the procedure.\n\nAdd it all up, and Inari's retrieval device seems like an obvious choice.\nThe company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.\nInari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.\nNovavax: How high can it go?\nTaylor Carmichael (Novavax): The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.\nNVAX DATA BY YCHARTS.\nPositive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.\nDespite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.\nIn the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told The New York Times.\nDown the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.","news_type":1,"symbols_score_info":{"NVAX":0.9,"NARI":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803293762,"gmtCreate":1627439678656,"gmtModify":1633764963590,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574328305423311","idStr":"3574328305423311"},"themes":[],"htmlText":"Anyone drinking beers","listText":"Anyone drinking beers","text":"Anyone drinking beers","images":[{"img":"https://static.tigerbbs.com/2bfc4834d8c3e481cb02a247326c4a8f","width":"1125","height":"2793"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/803293762","isVote":1,"tweetType":1,"viewCount":1234,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":809384115,"gmtCreate":1627348416737,"gmtModify":1633765884119,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574328305423311","idStr":"3574328305423311"},"themes":[],"htmlText":"Nice beer, Samual Adam","listText":"Nice beer, Samual Adam","text":"Nice beer, Samual Adam","images":[{"img":"https://static.tigerbbs.com/8c81143c8d7d05e9c1d1bf9c10749ede","width":"1125","height":"2629"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/809384115","isVote":1,"tweetType":1,"viewCount":1366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":178477161,"gmtCreate":1626834797553,"gmtModify":1633770545641,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574328305423311","idStr":"3574328305423311"},"themes":[],"htmlText":"😱😱😱","listText":"😱😱😱","text":"😱😱😱","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/178477161","repostId":"2153761308","repostType":2,"repost":{"id":"2153761308","kind":"highlight","pubTimestamp":1626834023,"share":"https://www.laohu8.com/m/news/2153761308?lang=zh_CN&edition=full","pubTime":"2021-07-21 10:20","market":"hk","language":"zh","title":"奈雪的茶跌近4% 较招股价已跌超35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2153761308","media":"新浪港股","summary":"7月21日消息，奈雪的茶持续下跌，现跌3.82%，报13.08港元，最新市值224.34亿港元。\n 奈雪的茶于6月30日首挂上市，每股定价19.8港元。上市当日破发，此后股价持续下行，今日再度跌近4%，低见12.86港元，较招股价已跌超35%。\n\n\n海量资讯、精准解读，尽在新浪财经APP","content":"<html><body><div>\n<div>\n<div>\n<img src=\"http://image.sinajs.cn/newchart/hk_stock/min_660/02150.gif\"/>\n</div>\n</div>\n<p> 7月21日消息，<span><a href=\"https://laohu8.com/S/02150\">奈雪的茶</a></span><span></span>持续下跌，现跌3.82%，报13.08港元，最新市值224.34亿港元。</p>\n<p> 奈雪的茶于6月30日首挂上市，每股定价19.8港元。上市当日破发，此后股价持续下行，今日再度跌近4%，低见12.86港元，较招股价已跌超35%。</p>\n<div>\n<div><img src=\"\"/></div>\n<div>海量资讯、精准解读，尽在<a href=\"https://laohu8.com/S/SINA\">新浪</a>财经APP</div>\n</div>\n</div></body></html>","source":"highlight_sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>奈雪的茶跌近4% 较招股价已跌超35%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n奈雪的茶跌近4% 较招股价已跌超35%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-21 10:20 北京时间 <a href=https://finance.sina.com.cn/stock/hkstock/marketalerts/2021-07-21/doc-ikqciyzk6703448.shtml><strong>新浪港股</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月21日消息，奈雪的茶持续下跌，现跌3.82%，报13.08港元，最新市值224.34亿港元。\n 奈雪的茶于6月30日首挂上市，每股定价19.8港元。上市当日破发，此后股价持续下行，今日再度跌近4%，低见12.86港元，较招股价已跌超35%。\n\n\n海量资讯、精准解读，尽在新浪财经APP</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2021-07-21/doc-ikqciyzk6703448.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/67b872f6d508e7d70db55d570f1b762b","relate_stocks":{"02150":"奈雪的茶"},"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2021-07-21/doc-ikqciyzk6703448.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2153761308","content_text":"7月21日消息，奈雪的茶持续下跌，现跌3.82%，报13.08港元，最新市值224.34亿港元。\n 奈雪的茶于6月30日首挂上市，每股定价19.8港元。上市当日破发，此后股价持续下行，今日再度跌近4%，低见12.86港元，较招股价已跌超35%。\n\n\n海量资讯、精准解读，尽在新浪财经APP","news_type":1,"symbols_score_info":{"02150":1}},"isVote":1,"tweetType":1,"viewCount":1150,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178473966,"gmtCreate":1626834447955,"gmtModify":1631885372374,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574328305423311","idStr":"3574328305423311"},"themes":[],"htmlText":"What about Nio; Xpeng Lucid etc etc ?","listText":"What about Nio; Xpeng Lucid etc etc ?","text":"What about Nio; Xpeng Lucid etc etc ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/178473966","repostId":"1110113604","repostType":4,"repost":{"id":"1110113604","kind":"news","pubTimestamp":1626833437,"share":"https://www.laohu8.com/m/news/1110113604?lang=zh_CN&edition=full","pubTime":"2021-07-21 10:10","market":"us","language":"en","title":"Why Goldman Sachs Is Bullish On Tesla Ahead Of Q2 Earnings<blockquote>为什么高盛在第二季度财报公布前看好特斯拉</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1110113604","media":"Benzinga","summary":"Tesla, Inc.(NASDAQ:TSLA)shares have been locked in a lackluster phase in 2021.\nAn upcoming catalyst ","content":"<p><div> Tesla, Inc.(NASDAQ:TSLA)shares have been locked in a lackluster phase in 2021. An upcoming catalyst that could meaningfully move the stock are the company's quarterly results, due July 26 after the ...</p><p><blockquote><div>特斯拉公司（纳斯达克：TSLA）的股价在2021年一直处于低迷阶段。即将到来的可能对该股产生有意义影响的催化剂是该公司的季度业绩，该业绩将于7月26日公布。</div></blockquote></p><p> <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/21/07/22065347/why-goldman-sachs-is-bullish-on-tesla-ahead-of-q2-earnings\">网页链接</a> </div> </p><p><blockquote><a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/21/07/22065347/why-goldman-sachs-is-bullish-on-tesla-ahead-of-q2-earnings\">网页连接</a></blockquote></p><p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Goldman Sachs Is Bullish On Tesla Ahead Of Q2 Earnings<blockquote>为什么高盛在第二季度财报公布前看好特斯拉</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Goldman Sachs Is Bullish On Tesla Ahead Of Q2 Earnings<blockquote>为什么高盛在第二季度财报公布前看好特斯拉</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2021-07-21 10:10</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Tesla, Inc.(NASDAQ:TSLA)shares have been locked in a lackluster phase in 2021. An upcoming catalyst that could meaningfully move the stock are the company's quarterly results, due July 26 after the ...</p><p><blockquote><div>特斯拉公司（纳斯达克：TSLA）的股价在2021年一直处于低迷阶段。即将到来的可能对该股产生有意义影响的催化剂是该公司的季度业绩，该业绩将于7月26日公布。</div></blockquote></p><p> <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/21/07/22065347/why-goldman-sachs-is-bullish-on-tesla-ahead-of-q2-earnings\">网页链接</a> </div> </p><p><blockquote><a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/21/07/22065347/why-goldman-sachs-is-bullish-on-tesla-ahead-of-q2-earnings\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/21/07/22065347/why-goldman-sachs-is-bullish-on-tesla-ahead-of-q2-earnings\">Benzinga</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.benzinga.com/analyst-ratings/analyst-color/21/07/22065347/why-goldman-sachs-is-bullish-on-tesla-ahead-of-q2-earnings","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1110113604","content_text":"Tesla, Inc.(NASDAQ:TSLA)shares have been locked in a lackluster phase in 2021.\nAn upcoming catalyst that could meaningfully move the stock are the company's quarterly results, due July 26 after the close.\nThe Tesla Analyst:Goldman Sachs analyst Mark Delaney has a Buy rating and $860 price target for Tesla shares.\nThe Tesla Takeaways:Tesla is likely to report in-line second-quarter results, premised onstrong quarterly deliveries, Delaney said in a note.\nA combination of chip shortages, high freight costs and increasing input costs will offset strong sales numbers, the analyst said.\nThe consensus expectations for Tesla's second-quarter call for earnings of 96 cents per share on revenues of $11.21 billion, up an estimated 85.5% year-over-year.\nGoldman is positive on Tesla stock this earnings season, Delaney said.\nThere is likely to be upside to second-half 2021 and 2022 consensus estimates, primarily due to strong Model Y SUV sales, the analyst said. The company released a new lower-cost version of the SUV in China and is ramping three new factories all focused on the Model Y, he said.\n\"All else equal, we believe a higher mix of Model Y deliveries should be a tailwind to margins given its higher price points but similar cost structure to the Model 3,\" Delaney said.\nThe analyst expects higher volumes and the company's leadership position in the rapidly growing EV market to lead to strong revenue and margin growth.\nTSLA Price Action:Tesla shares were up 2.21% at $660.50 at the close Tuesday.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":1378,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178447118,"gmtCreate":1626834329134,"gmtModify":1633770552301,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574328305423311","idStr":"3574328305423311"},"themes":[],"htmlText":"What happen to Blue zmoon? Turning to Red Moon now","listText":"What happen to Blue zmoon? Turning to Red Moon now","text":"What happen to Blue zmoon? Turning to Red Moon now","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/178447118","repostId":"2153137486","repostType":4,"isVote":1,"tweetType":1,"viewCount":1397,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171610471,"gmtCreate":1626741415893,"gmtModify":1633771552111,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574328305423311","idStr":"3574328305423311"},"themes":[],"htmlText":"Chewy! Chewy!","listText":"Chewy! Chewy!","text":"Chewy! Chewy!","images":[{"img":"https://static.tigerbbs.com/f02a25ede97c39da8a92b841931a4183","width":"1125","height":"2425"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/171610471","isVote":1,"tweetType":1,"viewCount":1124,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}